{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:47:29Z","timestamp":1776311249862,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Bullous pemphigoid (BP) is an autoimmune bullous disease caused by circulating autoantibodies toward the hemidesmosomal antigens BP180 and BP230. Cases of BP have been described following vaccinations against tetanus, poliomyelitis, diphtheria, influenza, pneumococcus, meningococcus, hepatitis B and rabies. The putative mechanism by which COVID-19-vaccines may induce BP has not been clarified. An Italian multicentre study was conducted to collect clinical, histopathological and immunopathological data of patients with BP associated with COVID-19-vaccines. Twenty-one cases were collected, including 9 females and 12 males (M\/F = 1.3) with a median age at diagnosis of 82 years. Seventeen patients received the COMIRNATY Pfizer-BioNTech vaccine, two the Moderna mRNA-1273 vaccine, one the ChAdOx1\/nCoV-19-AstraZeneca\/ Vaxzevria vaccine and one received the first dose with the ChAdOx1\/nCoV-19-AstraZeneca\/Vaxzevria vaccine and the second dose with the COMIRNATY Pfizer-BioNTech vaccine. Median latency time between the first dose of anti-SARS-CoV-2 vaccine and the onset of cutaneous manifestations was 27 days. Median BPDAI at onset was 42. Eleven out of seventeen patients (65%) had positive titres for anti-BP180 antibodies with a median value of 106.3 U\/mL on ELISA; in contrast, only five out of seventeen (29%) were positive for anti-BP230 antibodies, with a median of 35.3 U\/mL. In conclusion, in terms of mean age, disease severity at diagnosis and clinical phenotype vaccine-associated BP patients seem to be similar to idiopathic BP with an overall benign course with appropriate treatment. On the other hand, the slight male predominance and the reduced humoral response to BP230 represent peculiar features of this subset of patients.<\/jats:p>","DOI":"10.3389\/fmed.2022.841506","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T07:29:29Z","timestamp":1646033369000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Carlo Alberto","family":"Maronese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Caproni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Moltrasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Vezzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Sena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Previtali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Parodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Atzori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Antiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Maglie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena Biancamaria","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Corr\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabatino","family":"Pallotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biagio","family":"Didona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Zenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","article-title":"Bullous pemphigoid: a review of its diagnosis, associations and treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/pde.12231","article-title":"Postvaccination bullous pemphigoid in infancy: report of three new cases and literature review","volume":"30","author":"de la Fuente","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"B3","first-page":"1328","article-title":"Bullous pemphigoid after herpes zoster vaccine administration: association or coincidence?","volume":"10","author":"Chac\u00f3n","year":"2011","journal-title":"J Drugs Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3315\/jdcr.2011.1081","article-title":"Bullous pemphigoid triggered by swine flu vaccination: case report and review of vaccine triggered pemphigoid","volume":"5","author":"Walmsley","year":"2011","journal-title":"J Dermatol Case Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/biom10101432","article-title":"Bullous pemphigoid: trigger and predisposing factors","volume":"10","author":"Moro","year":"2020","journal-title":"Biomolecules."},{"key":"B6","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1365-2133.2006.07411.x","article-title":"Bullous pemphigoid triggered by influenza vaccination? Ecological study in Galicia, Spain","volume":"155","author":"Garc\u00eda-Doval","year":"2006","journal-title":"Br J Dermatol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15626","article-title":"Case of pemphigoid with immunoglobulin G antibodies to BP180 C-terminal domain and laminin-\u03b31 (p200) developed after pneumococcal vaccination","author":"Maki","year":"2021","journal-title":"J Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1111\/bjd.19480","article-title":"Infantile bullous pemphigoid following serogroup B meningococcal vaccination","volume":"184","author":"Navarro-Navarro","year":"2021","journal-title":"Br J Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4103\/ijdvl.IJDVL_666_18","article-title":"Bullous pemphigoid triggered by rabies vaccine","volume":"86","author":"Jindal","year":"2020","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1684\/ejd.2018.3383","article-title":"Infantile bullous pemphigoid following vaccination","volume":"28","author":"Guerra","year":"2018","journal-title":"Eur J Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2021.06.026","article-title":"Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination","volume":"148","author":"Tomayko","year":"2021","journal-title":"J Allergy Clin Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1111\/jdv.17472","article-title":"The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?","volume":"35","author":"Damiani","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1111\/jdv.17722","article-title":"Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy","volume":"36","author":"Schmidt","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.061","article-title":"Association between vaccination and autoimmune bullous diseases: A systematic review","author":"Kasperkiewicz","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"617089","DOI":"10.3389\/fimmu.2020.617089","article-title":"Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases","volume":"11","author":"Vojdani","year":"2021","journal-title":"Front Immunol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20890","article-title":"Bullous pemphigoid after SARS-CoV-2 vaccination: spike protein-directed immunofluorescence confocal microscopy and T cell receptor studies","author":"Gambichler","year":"2021","journal-title":"Br J Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/1523-1747.ep12259692","article-title":"Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin","volume":"82","author":"Gammon","year":"1984","journal-title":"J Invest Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/bjd.20639","article-title":"Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases","volume":"186","author":"Catal\u00e0","year":"2021","journal-title":"Br J Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1111\/jdv.17343","article-title":"Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy","volume":"35","author":"Farinazzo","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaad.2021.09.002","article-title":"Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study","volume":"86","author":"McMahon","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1016\/j.medcle.2021.05.004","article-title":"Bullous pemphigoid and COVID-19 vaccine","volume":"157","author":"P\u00e9rez-L\u00f3pez","year":"2021","journal-title":"Med Clin."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e15208","DOI":"10.1111\/dth.15208","article-title":"Bullous pemphigoid triggered by COVID-19 vaccine: rapid resolution with corticosteroid therapy","volume":"35","author":"Dell'Antonia","year":"2021","journal-title":"Dermatol Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.annder.2021.07.008","article-title":"Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine","volume":"149","author":"Agharbi","year":"2021","journal-title":"Ann Dermatol Venereol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1111\/jdv.17676","article-title":"A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine","volume":"36","author":"Young","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1111\/1346-8138.16170","article-title":"Case of bullous pemphigoid following coronavirus disease 2019 vaccination","volume":"48","author":"Nakamura","year":"2021","journal-title":"J Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/cup.14104","article-title":"Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination","volume":"49","author":"Larson","year":"2022","journal-title":"J Cutan Pathol"},{"key":"B29","unstructured":""},{"key":"B30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1365-2133.1995.tb00739.x","article-title":"Induced bullous pemphigoid","volume":"132","author":"Venning","year":"1995","journal-title":"Br J Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"102743","DOI":"10.1016\/j.jaut.2021.102743","article-title":"A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases","volume":"125","author":"Tzioufas","year":"2021","journal-title":"J Autoimmun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1111\/jdv.17207","article-title":"Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic","volume":"35","author":"Kasperkiewicz","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00403-016-1631-1","article-title":"Evaluation of ELISA testing for BP180 and BP230 as a diagnostic modality for bullous pemphigoid: a clinical experience","volume":"308","author":"Keller","year":"2016","journal-title":"Arch Dermatol Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"272","DOI":"10.12932\/AP-231118-0446","article-title":"Anti-BP180 and anti-BP230 enzyme-linked immunosorbent assays for diagnosis and disease activity tracking of bullous pemphigoid: A prospective cohort study","volume":"39","author":"Chanprapaph","year":"2019","journal-title":"Asian Pac J Allergy Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1038\/jid.2011.180","article-title":"Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study","volume":"131","author":"Di Zenzo","year":"2011","journal-title":"J Invest Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3389\/fimmu.2019.01410","article-title":"Immune reaction to type XVII collagen induces intramolecular and intermolecular epitope spreading in experimental bullous pemphigoid models","volume":"10","author":"Ujiie","year":"2019","journal-title":"Front Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/j.1365-2133.2009.09266.x","article-title":"IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses","volume":"161","author":"Feliciani","year":"2009","journal-title":"Br J Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"108665","DOI":"10.1016\/j.clim.2021.108665","article-title":"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases?","volume":"224","author":"Talotta","year":"2021"},{"key":"B40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/1346-8138.13031","article-title":"Role of physical factors in the pathogenesis of bullous pemphigoid: Case report series and a comprehensive review of the published work","volume":"43","author":"D\u0103nescu","year":"2016","journal-title":"J Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: a review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.841506\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T07:29:31Z","timestamp":1646033371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.841506\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":41,"alternative-id":["10.3389\/fmed.2022.841506"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.841506","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"article-number":"841506"}}